Turn Therapeutics Inc.
TTRXNASDAQHealthcareBiotechnology
Previous close
$9.46
−$0.08 · -0.84%
TTRX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
39
Expensive
Momentum
92
Strong Up
Sentiment
55
Mixed
Risk resilience
19
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTurn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Bradley E. Burnam
- Listed since
- Oct 8, 2025
- Employees
- 2
Market position
Day range
Current $9.46
52-week range
Current $9.46
- Open
- $9.635
- Previous close
- $9.54
- Volume
- 22.23K
- 0.34× average
- Average volume
- 66K
- Average daily volume
- Market cap
- 281.79M USD
- Beta
- 2.02
- Market reference 1
- 50-day average
- $8.4311
- +12.20% above average
- 200-day average
- $5.0264
- +88.21% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 49.16M USD
- P/E (TTM)
- -32.46×
- P/B (TTM)
- 410.25×
- P/S (TTM)
- 0×
- EV / EBITDA
- -15.65×
- Earnings yield
- -5.90%
- Free cash flow yield
- -5.02%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -68.15%
- Return on assets
- -26.26%
- Return on invested capital
- -94.42%
Financial health
- Debt / equity
- 8.91×
- Current ratio
- 0.87×
- Altman Z-score
- 7.27
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development | 265.57K USD | 245.96K USD | 7.5K USD |
| Selling, general, and administrative | 5.59M USD | 1.55M USD | 2.3M USD |
| Operating expenses | 5.86M USD | 1.8M USD | 2.31M USD |
| Interest income | 29.58K USD | 28.71K USD | 15.88K USD |
| Depreciation and amortization | 52.75K USD | 47.48K USD | 43.92K USD |
| Operating income | −5.86M USD | −1.8M USD | −2.31M USD |
| Net income | −3.19M USD | −1.77M USD | −2.29M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 25%
- 1 beat, 3 misses, 0 met estimates
- Average EPS surprise
- -217.16%
- 4 comparable reports
- Latest EPS result
- -0.2
- Estimate -0.02 · Miss by 900.00%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
TTRX news
TTRX peers
ETFs holding TTRX
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research TTRXresearch.disclaimer